Our breakthrough, proprietary technology platform engineered to enhance drug absorption
End-to-end, in-house control of formulation, development, and manufacturing capabilities
Our proprietary cannabinoid composition for the management of pain and inflammation
Partnering with the world’s leading research institutions and doctors to support FDA-authorized investigator-initiated clinical trials
Learn more about cannabidiol from the medical community and regulators
We are modernizing the way medicines are taken
Experts in drug development and delivery, manufacturing, and commercialization
Recent media coverage regarding Orcosa
Company news and announcements
RITe™ tablets disintegrate in less than 3 seconds, rapidly adhering to the absorption site and delivering an active ingredient through the tissue in your cheek.
No water needed for RITe™ tablets
Effects felt in minutes
Same effects, lower dose
Addresses pain points of drug delivery
July 22, 2022 – Orcosa is pleased to report the enrollment of the first patient participating in an investigator-initiated Phase 2 clinical trial utilizing ORAVEXX™ (cannabidiol, CBD) at NYU Langone Health Orthopedic Hospital (“NYU Langone”). The trial (NCT05020028), an investigator-initiated randomized, double-blind, placebo-controlled clinical trial led by Principal Investigator Dr. Michael J. Alaia of NYU Langone, aims […]
July 14, 2022 EWING, N.J.–(BUSINESS WIRE)–Orcosa Inc. (“Orcosa” or the “Company”), a clinical-stage life sciences company improving patient outcomes through its next generation drug delivery technology – the Rapid Infusion Technology (RITe™) Platform – today announced the appointment of Dr. Andrew C. von Eschenbach, former Commissioner of the U.S. Food and Drug Administration (“FDA”) as Senior […]
Infographic: Learn More About How the RITe™ Platform Works Infographic: Learn More About ORAVEXX™ Ewing, NJ – March 25, 2022 – Orcosa Inc. (“Orcosa” or the “Company”), a life sciences company modernizing the way medicines are taken through its next generation drug delivery technology – the Rapid Infusion Technology (RITe™) Platform – today announced its […]
December 27, 2021 – Orcosa is pleased to report the dosing of the final patient participating in an investigator-initiated multicenter Phase 1/2 clinical trial utilizing ORAVEXX™ at NYU Langone Health Orthopedic Hospital (“NYU Langone”). The trial (NCT04672252), an investigator-initiated multicenter, randomized, double-blind, placebo-controlled clinical trial led by Principal Investigator Dr. Michael J. Alaia of NYU […]